Oxaliplatin in the treatment of colorectal cancer

Bibliography

• KIDANI Y, INAGAKI K, TSUKAGOSHI S: Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. Gann (1976) 67(6):921-922.
   PubMedGoogle Scholar
• CONNORS TA, JONES M, ROSS WC et al.: New platinum complexes with anti-tumour activity. Chem. Biol. Interact. (1972) 5(6):415-424.
   PubMed Web of Science ®Google Scholar
• CVITKOVIC E, BEKRADDA M: Oxaliplatin: a new therapeutic option in colorectal cancer. Semin. Oncol. (1999) 26(6):647-662.
   PubMed Web of Science ®Google Scholar
• SARIS CP, VAN DE VAART PJ, RIETBROEK RC, BLOMMAERT FA: In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis (1996) 17(12):2763-2769.
   PubMed Web of Science ®Google Scholar
• SCHEEFF ED, BRIGGS JM, HOWELL SB: Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol. Pharmacol. (1999) 56(3):633-643.
   PubMed Web of Science ®Google Scholar
• RAYMOND E, FAIVRE S, WOYNAROWSKI JM, CHANEY SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. (1998) 25(2 Suppl. 5):4-12.
   PubMed Web of Science ®Google Scholar
• ALLEN J, GRAHAM MA, FIRTH J et al.: Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer. Proc. Am. Assoc. Cancer Res. (1998) 39:159.
   Google Scholar
• LIN X, OKUDA T, HOLZER A, HOWELL SB: The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol. (2002) 62(5):1154-1159.
   PubMed Web of Science ®Google Scholar
• TSUCHIDA S, SATO K: Glutathione transferases and cancer. Crit. Rev. Biochem. Mol. Biol. (1992) 27(4):337-384.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI M, KOHNO K, SABURI Y et al.: Drug resistance to cis-diamminedichloroplatinum (II) in Chinese hamster ovary cell lines transfected with glutathione S-transferase pi gene. Biochem. Biophys. Res. Commun. (1990) 166(3):1358-1364.
   PubMed Web of Science ®Google Scholar
• FERRY KV, HAMILTON TC, JOHNSON SW: Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol. (2000) 60(9):1305-1313.
   PubMed Web of Science ®Google Scholar
• ARNOULD S, HENNEBELLE I, CANAL P, BUGAT R, GUICHARD S: Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur. J. Cancer (2003) 39(1):112-119.
   PubMed Web of Science ®Google Scholar
• PLASENCIA C, MARTINEZ-BALIBREA E, MARTINEZ-CARDUS A et al.: Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT-29 colon cancer cells. Int. J. Oncol. (2006) 29(1):225-235.
   PubMed Web of Science ®Google Scholar
• PARK DJ, STOEHLMACHER J, ZHANG W et al.: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. (2001) 61(24):8654-8658.
   PubMed Web of Science ®Google Scholar
• CHU G, CHANG E: Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc. Natl. Acad. Sci. USA (1990) 87(9):3324-3327.
   PubMed Web of Science ®Google Scholar
• AEBI S, KURDI-HAIDAR B, GORDON R et al.: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. (1996) 56(13):3087-3090.
   PubMed Web of Science ®Google Scholar
• FINK D, NEBEL S, AEBI S et al.: The role of DNA mismatch repair in platinum drug resistance. Cancer Res. (1996) 56(21):4881-4886.
   PubMed Web of Science ®Google Scholar
• ZDRAVESKI ZZ, MELLO JA, FARINELLI CK, ESSIGMANN JM, MARINUS MG: MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J. Biol. Chem. (2002) 277(2):1255-1260.
   PubMed Web of Science ®Google Scholar
• KARRAN P, BIGNAMI M: DNA damage tolerance, mismatch repair and genome instability. Bioessays (1994) 16(11):833-839.
   PubMed Web of Science ®Google Scholar
• HEINEN CD, WILSON T, MAZUREK A et al.: HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 molecular switch functions. Cancer Cell (2002) 1(5):469-478.
   PubMed Web of Science ®Google Scholar
• DUNN TA, SCHMOLL HJ, GRUNWALD V, BOKEMEYER C, CASPER J: Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest. New Drugs (1997) 15(2):109-114.
   PubMed Web of Science ®Google Scholar
• FUKUDA M, OHE Y, KANZAWA F et al.: Evaluation of novel platinum complexes, inhibitors of topoisomerase I, II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anti-Cancer Res. (1995) 15(2):393-398.
   PubMed Web of Science ®Google Scholar
• KRAKER AJ, MOORE CW: Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res. (1988) 48(1):9-13.
   PubMed Web of Science ®Google Scholar
• RAYMOND E, BUQUET-FAGOT C, DJELLOUL S et al.: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs (1997) 8(9):876-885.
   PubMed Web of Science ®Google Scholar
• RIXE O, ORTUZAR W, ALVAREZ M et al.: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem. Pharmacol. (1996) 52(12):1855-1865.
   PubMed Web of Science ®Google Scholar
• BOYER J, MCLEAN EG, AROORI S et al.: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin. Cancer Res. (2004) 10(6):2158-2167.
   PubMed Web of Science ®Google Scholar
• BOYER J, ALLEN WL, MCLEAN EG et al.: Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. (2006) 66(5):2765-2777.
   PubMed Web of Science ®Google Scholar
• PENDYALA L, CREAVEN PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. (1993) 53(24):5970-5976.
   PubMed Web of Science ®Google Scholar
• GRAHAM MA, LOCKWOOD GF, GREENSLADE D et al.: Clinical pharmacokinetics of oxaliplatin: a critical review. Clin. Cancer Res. (2000) 6(4):1205-1218.
   PubMed Web of Science ®Google Scholar
• CULY CR, CLEMETT D, WISEMAN LR: Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs (2000) 60(4):895-924.
   PubMed Web of Science ®Google Scholar
• EXTRA JM, MARTY M, BRIENZA S, MISSET JL: Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol. (1998) 25(2 Suppl. 5):13-22.
   PubMed Web of Science ®Google Scholar
• LEVI F, METZGER G, MASSARI C, MILANO G: Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. (2000) 38(1):1-21.
   PubMed Web of Science ®Google Scholar
• TAGUCHI T, TSUKAGOSHI S, FURUE H, NIITANI H, NODA K: [Phase I clinical study of oxaliplatin]. Gan To Kagaku Ryoho (1998) 25(12):1899-1907.
   PubMedGoogle Scholar
• GAMELIN E, BOUIL AL, BOISDRON-CELLE M et al.: Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res. (1997) 3(6):891-899.
   PubMed Web of Science ®Google Scholar
• LUO FR, WYRICK SD, CHANEY SG: Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol. Res. (1998) 10(11-12):595-603.
   PubMed Web of Science ®Google Scholar
• TAKIMOTO CH, REMICK SC, SHARMA S et al.: Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J. Clin. Oncol. (2003) 21(14):2664-2672.
   PubMed Web of Science ®Google Scholar
• DOROSHOW JH, SYNOLD TW, GANDARA D et al.: Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin. Oncol. (2003) 30(4 Suppl. 15):14-19.
   PubMed Web of Science ®Google Scholar
• APARICIO T, DESRAME J, LECOMTE T et al.: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br. J. Cancer (2003) 89(8):1439-1444.
   PubMed Web of Science ®Google Scholar
• WASSERMAN E, CUVIER C, LOKIEC F et al.: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent Phase I studies with pharmacokinetics. J. Clin. Oncol. (1999) 17(6):1751-1759.
   PubMed Web of Science ®Google Scholar
• LEVI F, PERPOINT B, GARUFI C et al.: Oxaliplatin activity against metastatic colorectal cancer. A Phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer (1993) 29A(9):1280-1284.
   PubMed Web of Science ®Google Scholar
• MACHOVER D, DIAZ-RUBIO E, DE GRAMONT A et al.: Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. (1996) 7(1):95-98.
   PubMed Web of Science ®Google Scholar
• BECOUARN Y, YCHOU M, DUCREUX M et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol. (1998) 16(8):2739-2744.
   PubMed Web of Science ®Google Scholar
• DIAZ-RUBIO E, SASTRE J, ZANIBONI A et al.: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a Phase II multicentric study. Ann. Oncol. (1998) 9(1):105-108.
   PubMed Web of Science ®Google Scholar
• ZORI COMBA A, BLAJMAN C, RICHARDET E et al.: A randomised Phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur. J. Cancer (2001) 37(8):1006-1013.
   PubMed Web of Science ®Google Scholar
• GIACCHETTI S, PERPOINT B, ZIDANI R et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. (2000) 18(1):136-147.
   PubMed Web of Science ®Google Scholar
• DE GRAMONT A, FIGER A, SEYMOUR M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. (2000) 18(16):2938-2947.
   PubMed Web of Science ®Google Scholar
• GROTHEY A, DESCHLER B, KROENING H et al.: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) versus weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol. (2002) 21.
   Google Scholar
• ROTHENBERG ML, OZA AM, BIGELOW RH et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol. (2003) 21(11):2059-2069.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RM, SARGENT DJ, MORTON RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2004) 22(1):23-30.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RM, SARGENT DJ, MORTON RF et al.: N9741: FOLFOX (oxaliplatin(Oxal)/5-fluorouracil (5-FU)/leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study. ASCO Meeting Abstracts (2004) 22(Suppl. 14):3621.
   Google Scholar
• GAMELIN E, GAMELIN L, BOSSI L, QUASTHOFF S: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin. Oncol. (2002) 29(5 Suppl. 15):21-33.
   PubMed Web of Science ®Google Scholar
• CASSIDY J, MISSET JL: Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. (2002) 29(5 Suppl. 15):11-20.
   PubMed Web of Science ®Google Scholar
• LEVI F, MISSET JL, BRIENZA S et al.: A chronopharmacologic Phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer (1992) 69(4):893-900.
   PubMed Web of Science ®Google Scholar
• CAUSSANEL JP, LEVI F, BRIENZA S et al.: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst. (1990) 82(12):1046-1050.
   PubMed Web of Science ®Google Scholar
• BARHAMAND B: Management of pharyngolaryngeal dysesthesia associated with oxaliplatin therapy. Clin. J. Oncol. Nurs. (2003) 7(4):452-453.
   PubMedGoogle Scholar
• TRISOLINI R, LAZZARI AGLI L, TASSINARI D et al.: Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur. Respir. J. (2001) 18(1):243-245.
   PubMed Web of Science ®Google Scholar
• STAHL M, KOSTER W, WILKE H: Reaction after oxaliplatin-prevention with corticosteroids? Ann. Oncol. (2001) 12(6):874.
   PubMed Web of Science ®Google Scholar
• TOURNIGAND C, MAINDRAULT-GOEBEL F, LOUVET C, DE GRAMONT A, KRULIK M: Severe anaphylactic reactions to oxaliplatin. Eur. J. Cancer (1998) 34(8):1297-1298.
   PubMed Web of Science ®Google Scholar
• DESRAME J, BROUSTET H, DARODES DE TAILLY P, GIRARD D, SAISSY JM: Oxaliplatin-induced haemolytic anaemia. Lancet (1999) 354(9185):1179-1180.
   PubMedGoogle Scholar
• RAYMOND E, CHANEY SG, TAAMMA A, CVITKOVIC E: Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. (1998) 9(10):1053-1071.
   PubMed Web of Science ®Google Scholar
• BRIENZA SVJ, ITZHAKI M, KRIKORIAN A: Oxaliplatin: global safety in 682 patients. Proc. Am. Soc. Clin. Oncol. (1995) 14(Abstract 513):209.
   Google Scholar
• GORNET JM, SAVIER E, LOKIEC F et al.: Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann. Oncol. (2002) 13(8):1315-1318.
   PubMed Web of Science ®Google Scholar
• GROLLEAU F, GAMELIN L, BOISDRON-CELLE M et al.: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. (2001) 85(5):2293-2297.
   PubMed Web of Science ®Google Scholar
• ADELSBERGER H, QUASTHOFF S, GROSSKREUTZ J et al.: The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur. J. Pharmacol. (2000) 406(1):25-32.
   PubMed Web of Science ®Google Scholar
• LEHKY TJ, LEONARD GD, WILSON RH, GREM JL, FLOETER MK: Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve (2004) 29(3):387-392.
   PubMed Web of Science ®Google Scholar
• HOLMES J, STANKO J, VARCHENKO M et al.: Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol. Sci. (1998) 46(2):342-351.
   PubMed Web of Science ®Google Scholar
• COURT WS, ORDER SE, SIEGEL JA et al.: Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest. (2002) 20(5-6):613-625.
   PubMed Web of Science ®Google Scholar
• SCRENCI D, MCKEAGE MJ, GALETTIS P et al.: Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br. J. Cancer (2000) 82(4):966-972.
   PubMed Web of Science ®Google Scholar
• SHORD SS, BERNARD SA, LINDLEY C et al.: Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. Anti-Cancer Res. (2002) 22(4):2301-2309.
   PubMed Web of Science ®Google Scholar
• GREEN E, SARGENT DJ, GOLDBERG RM, GROTHEY A: Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741. Proc. Am. Soc. Clin. Oncol. (2005) 23.
   Google Scholar
• TOURNIGAND C, CERVANTES A, FIGER A et al.: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study. J. Clin. Oncol. (2006) 24(3):394-400.
   PubMed Web of Science ®Google Scholar
• MAINDRAULT-GOEBEL F, LLEDO G, CHIBAUDEL B et al.: OPTIMOX2, a large randomized Phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):3504.
   PubMed Web of Science ®Google Scholar
• GAMELIN L, BOISDRON-CELLE M, DELVA R et al.: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res. (2004) 10(12 Pt 1):4055-4061.
   PubMed Web of Science ®Google Scholar
• AGAFITEI RD, SCHNEIDER S, IQBAL S et al.: Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX). J. Clin. Oncol. (Meeting Abstracts) (2004) 22(Suppl. 14):3600.
   Google Scholar
• MARIANI G, GRANETT C, NUMICO G et al.: Oxaliplatin induced neuropathy: could gabapentin be the answer? Proc. Am. Soc. Clin. Oncol. (2000) 19:2397.
   Web of Science ®Google Scholar
• WILSON RH, LEHKY T, THOMAS RR et al.: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J. Clin. Oncol. (2002) 20(7):1767-1774.
   PubMed Web of Science ®Google Scholar
• VON DELIUS S, ECKEL F, WAGENPFEIL S et al.: Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter Phase II study. Invest. New Drugs (2007) 25(2):173-180.
   Google Scholar
• PENZ M, KORNEK GV, RADERER M et al.: Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann. Oncol. (2001) 12(3):421-422.
   PubMed Web of Science ®Google Scholar
• RUDOLPH S, KUHN R, LIPPERT H: Randomised trial with or without amifostin to reduce neurotoxicity side effects under chemotherapy with oxaliplatin, FA/5-FU. Ann. Oncol. (2000) 11(Suppl. 4):154-155.
   Google Scholar
• CASCINU S, CATALANO V, CORDELLA L et al.: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. (2002) 20(16):3478-3483.
   PubMed Web of Science ®Google Scholar
• PRADINES A, MAGAZIN M, SCHILTZ P et al.: Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J. Neurochem. (1995) 64(5):1954-1964.
   PubMed Web of Science ®Google Scholar
• CASSIDY J, BJARNASON GA, HICKISH T et al.: Randomized double blind (DB) placebo (Plcb) controlled Phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):3507.
   Google Scholar
• ANDRE T, BONI C, MOUNEDJI-BOUDIAF L et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. (2004) 350(23):2343-2351.
   PubMed Web of Science ®Google Scholar
• DE GRAMONT A, BONI C, NAVARRO M et al.: Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):3501.
   Google Scholar
• WOLMARK N, WIEAND S, KUEBLER JP, COLANGELO L, SMITH RE: A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):LBA3500.
   Google Scholar
• ADSON MA, VAN HEERDEN JA: Major hepatic resections for metastatic colorectal cancer. Ann. Surg. (1980) 191(5):576-583.
   PubMed Web of Science ®Google Scholar
• HUGHES KS, SIMON R, SONGHORABODI S et al.: Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery (1986) 100(2):278-284.
   PubMed Web of Science ®Google Scholar
• WEISS L, GRUNDMANN E, TORHORST J et al.: Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J. Pathol. (1986) 150(3):195-203.
   PubMed Web of Science ®Google Scholar
• BISMUTH H, ADAM R, LEVI F et al.: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. (1996) 224(4):509-520; discussion 520-502.
   PubMed Web of Science ®Google Scholar
• ALBERTS SR, HORVATH WL, STERNFELD WC et al.: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J. Clin. Oncol. (2005) 23(36):9243-9249.
   PubMed Web of Science ®Google Scholar
• TABERNERO JM, VAN CUTSEM E, SASTRE J et al.: An international Phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. J. Clin. Oncol. (Meeting Abstracts) (2004) 22(Suppl. 14):3512.
   Google Scholar
• DELAUNOIT T, ALBERTS SR, SARGENT DJ et al.: Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann. Oncol. (2005) 16(3):425-429.
   PubMed Web of Science ®Google Scholar
• BENOIST S, BROUQUET A, PENNA C et al.: Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J. Clin. Oncol. (2006) 24(24):3939-3945.
   PubMed Web of Science ®Google Scholar
• BILCHIK AJ, POSTON G, CURLEY SA et al.: Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J. Clin. Oncol. (2005) 23(36):9073-9078.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ FG, RITTER J, GOODWIN JW et al.: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J. Am. Coll. Surg. (2005) 200(6):845-853.
   PubMed Web of Science ®Google Scholar
• SEBAGH M, PLASSE M, LEVI F, ADAM R: Severe hepatic sinusoidal obstruction and oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer: a real entity? Ann. Oncol. (2005) 16(2):331; author reply 332-333.
   PubMed Web of Science ®Google Scholar
• TISMAN G, MACDONALD D, SHINDELL N et al.: Oxaliplatin toxicity masquerading as recurrent colon cancer. J. Clin. Oncol. (2004) 22(15):3202-3204.
   PubMedGoogle Scholar
• RUBBIA-BRANDT L, AUDARD V, SARTORETTI P et al.: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann. Oncol. (2004) 15(3):460-466.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
   PubMed Web of Science ®Google Scholar
• GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):2.
   Google Scholar
• HOCHSTER HS, WELLES L, HART L et al.: Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):3515.
   Google Scholar
• HOCHSTER HS, HART LL, RAMANATHAN RK et al.: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):3510.
   Web of Science ®Google Scholar
• SALTZ LB, CLARKE S, DIAZ-RUBIO E et al.: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer. GI ASCO (2007) 238.
   Google Scholar
• HEDRICK EE, HURWITZ H, SARKAR S et al.: Post-progression therapy (PPT) effect on survival in AVF2107, a Phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). J. Clin. Oncol. (Meeting Abstracts) (2004) 22(Suppl. 14):3517.
   PubMed Web of Science ®Google Scholar
• SCHLESSINGER J: Cell signaling by receptor tyrosine kinases. Cell (2000) 103(2):211-225.
   PubMed Web of Science ®Google Scholar
• YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. (2001) 2(2):127-137.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, MEROPOL NJ, LOEHRER PJ et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22(7):1201-1208.
   PubMed Web of Science ®Google Scholar
• DIAZ RUBIO E, TABERNERO J, VAN CUTSEM E et al.: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international Phase II study. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):3535.
   Google Scholar
• VENOOK A, NIEDZWIECKI D, HOLLIS D et al.: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) {+/-} cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):3509.
   PubMed Web of Science ®Google Scholar
• VAN HOUTEN B: Nucleotide excision repair in Escherichia coli. Microbiol. Mol. Biol. Rev. (1990) 54(1):18-51.
   Google Scholar
• HOEIJMAKERS JH: Nucleotide excision repair. II: From yeast to mammals. Trends Genet. (1993) 9(6):211-217.
   PubMed Web of Science ®Google Scholar
• SHIROTA Y, STOEHLMACHER J, BRABENDER J et al.: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. (2001) 19(23):4298-4304.
   PubMed Web of Science ®Google Scholar
• PARK DJ, STOEHLMACHER J, LENZ HJ: Tailoring chemotherapy in advanced colorectal cancer. Curr. Opin. Pharmacol. (2003) 3(4):378-385.
   PubMed Web of Science ®Google Scholar
• MCLEOD HL, MARSH S, FUCHS C et al.: Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer (CRC): Results from an intergroup trial. Proc. Am. Soc. Clin. Oncol. (2003) 22.
   PubMedGoogle Scholar
• STOEHLMACHER J, PARK DJ, ZHANG W et al.: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst. (2002) 94(12):936-942.
   PubMed Web of Science ®Google Scholar
• GROTHEY A, MCLEOD HL, GREEN EM et al.: Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):3509.
   PubMed Web of Science ®Google Scholar